List view / Grid view
1 December 2015 | By Victoria White
U3 Pharma is a clinical-stage biopharmaceutical company developing protein therapeutics for the treatment of diseases with serious unmet need, primarily cancer...
30 November 2015 | By Victoria White
By removing these interactions, the researchers partially restored the protein’s normal function. The findings suggest that therapies could one day treat the root cause of cystic fibrosis, not just the symptoms...
30 November 2015 | By Victoria White
This groundbreaking development could help advance a variety of liver-related research and applications...
30 November 2015 | By Victoria White
Heptares and Pfizer have announced they are to research and develop potential new medicines directed at up to 10 G protein-coupled receptor (GPCR) targets across multiple therapeutic areas...
30 November 2015 | By Victoria White
The aim of the project is to design a drug to inhibit a key parasite enzyme involved in the conversion of blood sugars to energy, to be effective in small doses, even on advanced infections, and kill the parasite...
30 November 2015 | By Victoria White
Faron Pharmaceuticals has announced the publication of data on the Clever-1 function related to its novel cancer immunotherapy antibody Clevegen...
27 November 2015 | By Victoria White
Researchers have discovered how connections between brain cells are destroyed in the early stages of Alzheimer’s disease...
27 November 2015 | By
Pelago and AstraZeneca will together develop assay formats and applications of the CETSA method relevant across the range of AstraZeneca’s therapeutic areas...
26 November 2015 | By Victoria White
Researchers from the University of Basel have, for the first time, successfully combined an antibody-drug conjugate with a therapy that stimulates the immune system to attack breast cancer cells...
26 November 2015 | By Victoria White
Venom Knowledge Base summarises the results of 5,117 studies in the medical literature describing the use of venom toxins as painkillers and as treatments for diseases...
26 November 2015 | By Victoria White
Scientists from the University of Toronto have switched off, one by one, almost 18,000 genes - 90% of the entire human genome - to find the genes that are essential for cell survival...
25 November 2015 | By Victoria White
The transaction, expected to complete next month, is aimed at strengthening ReproCELL’s pharmaceutical industry-targeted drug discovery services...
25 November 2015 | By Victoria White
Rugen has already demonstrated efficacy for its compounds in animal models of ASD and OCD...
25 November 2015 | By
Ablynx and Novo Nordisk hope to discover and develop novel multi-specific drug candidates using Ablynx's proprietary Nanobody technology...
25 November 2015 | By Victoria White
The companies have entered an agreement to discover and develop novel, small-molecule CGRP antagonists for the treatment of migraine...
